DAPA-CKD: Significant Victory for CKD with or without Diabetes

Sodium glucose cotransporter 2 inhibitors (SGLT2i) have revolutionized the treatment of heart failure and diabetic kidney disease. The DAPA-CKD trial by Heerspink et al. evaluated primary kidney outcomes with dapagliflozin in both diabetic and non-diabetic patients and identified kidney protection b...

Full description

Saved in:
Bibliographic Details
Published inTrends in endocrinology and metabolism Vol. 32; no. 6; pp. 335 - 337
Main Authors Patel, Ankit B., Mistry, Kavita, Verma, Ashish
Format Journal Article
LanguageEnglish
Published United States Elsevier Ltd 01.06.2021
Subjects
chronic kidney disease
DAPA-CKD
dapagliflozin
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
diabetic kidney disease
Diabetic Nephropathies - drug therapy
Endocrinology and Metabolism
Humans
Renal Insufficiency, Chronic - complications
Renal Insufficiency, Chronic - drug therapy
SGLT2 inhibitors
Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
diabetic kidney disease
chronic kidney disease
dapagliflozin
SGLT2 inhibitors
DAPA-CKD
Online AccessGet full text
ISSN1043-2760
1879-3061
1879-3061
DOI10.1016/j.tem.2021.02.007

Cover

More Information
Summary:Sodium glucose cotransporter 2 inhibitors (SGLT2i) have revolutionized the treatment of heart failure and diabetic kidney disease. The DAPA-CKD trial by Heerspink et al. evaluated primary kidney outcomes with dapagliflozin in both diabetic and non-diabetic patients and identified kidney protection by SGLT2i independent of diabetes mellitus.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1043-2760
1879-3061
1879-3061
DOI:10.1016/j.tem.2021.02.007